Shots:
- Merck has reported the P-IIb/III (BRUNELLO) trial data assessing remigromig (MK-3000; 0.5 & 0.8mg, IVT, Q4W) vs ranibizumab (0.5mg, Q4W) in 984 adults with diabetic macular edema (DME)
- In the trial, both remigromig doses met the 1EP, showing non-inferiority at 1yr. BCVA gains were +9.1 & +8.7 letters with 0.5 & 0.8mg, respectively, vs +11.8 letters, with no 2EP superiority observed; data were presented at AAO’26
- Data will be discussed with regulatory authorities, while remigromig is also being evaluated in the P-IIb/III (BAROLO) study for DME & in a PoC P-II (SUPER TUSCAN) trial for wet age-related macular degeneration & macular edema secondary to retinal vein occlusion
Ref: Businesswire | Image: Merck | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
